Siobhan Ng

9.6k total citations
33 papers, 708 citations indexed

About

Siobhan Ng is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Siobhan Ng has authored 33 papers receiving a total of 708 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Siobhan Ng's work include Prostate Cancer Treatment and Research (20 papers), Cancer Treatment and Pharmacology (11 papers) and Radiopharmaceutical Chemistry and Applications (10 papers). Siobhan Ng is often cited by papers focused on Prostate Cancer Treatment and Research (20 papers), Cancer Treatment and Pharmacology (11 papers) and Radiopharmaceutical Chemistry and Applications (10 papers). Siobhan Ng collaborates with scholars based in Australia, France and Netherlands. Siobhan Ng's co-authors include Mark Rosenthal, Karim Fizazi, Lawrence Cher, David M. Ashley, Joan Carles, Winald R. Gerritsen, H. Wang, Fred Saad, Frank Priou and Piotr Milecki and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Siobhan Ng

30 papers receiving 687 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Siobhan Ng Australia	12	360	355	169	161	119	33	708
Michele Prisciandaro Italy	15	270 0.8×	566 1.6×	83 0.5×	102 0.6×	157 1.3×	49	761
Albiruni Abdul Razak Canada	12	267 0.7×	425 1.2×	73 0.4×	108 0.7×	138 1.2×	37	726
C.J.A. Punt Netherlands	11	216 0.6×	299 0.8×	72 0.4×	88 0.5×	88 0.7×	26	624
Suriya Jeyapalan United States	13	263 0.7×	262 0.7×	109 0.6×	154 1.0×	92 0.8×	33	926
Noah Goodman United States	10	275 0.8×	381 1.1×	76 0.4×	162 1.0×	116 1.0×	12	646
Marius Lund‐Iversen Norway	17	523 1.5×	499 1.4×	43 0.3×	169 1.0×	279 2.3×	60	1.0k
Claudio Dansky Ullmann United States	14	136 0.4×	398 1.1×	54 0.3×	117 0.7×	275 2.3×	26	797
Rikiya Nakamura Japan	19	360 1.0×	622 1.8×	150 0.9×	49 0.3×	88 0.7×	61	984
Masato Sugano Japan	13	236 0.7×	427 1.2×	56 0.3×	135 0.8×	181 1.5×	44	709
I Tepler United States	11	151 0.4×	681 1.9×	121 0.7×	136 0.8×	217 1.8×	19	1.1k

Countries citing papers authored by Siobhan Ng

Since Specialization

Citations

This map shows the geographic impact of Siobhan Ng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Siobhan Ng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Siobhan Ng more than expected).

Fields of papers citing papers by Siobhan Ng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Siobhan Ng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Siobhan Ng. The network helps show where Siobhan Ng may publish in the future.

Co-authorship network of co-authors of Siobhan Ng

This figure shows the co-authorship network connecting the top 25 collaborators of Siobhan Ng. A scholar is included among the top collaborators of Siobhan Ng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Siobhan Ng. Siobhan Ng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marx, Gavin, Simon Chowdhury, Laurence E. Krieger, et al.. (2024). A practical guide for the use of apalutamide for non‐metastatic castration‐resistant prostate cancer in Australia. Asia-Pacific Journal of Clinical Oncology. 20(4). 435–443.

Jiang, Di, Hao‐Wen Sim, Lillian L. Siu, et al.. (2023). Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer. Clinical Colorectal Cancer. 22(4). 457–463.

Emmett, Louise, Shalini Subramaniam, Megan Crumbaker, et al.. (2023). LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). Annals of Oncology. 34. S1325–S1325. 7 indexed citations

Weickhardt, Andrew, Farshad Foroudi, Nathan Lawrentschuk, et al.. (2023). Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502). European Urology Oncology. 7(3). 469–477. 11 indexed citations

Gulley, James L., Michael Borre, Nicholas J. Vogelzang, et al.. (2019). Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 37(13). 1051–1061. 183 indexed citations

Weickhardt, Andrew, Farshad Foroudi, Shomik Sengupta, et al.. (2018). Pembrolizumab and chemoradiotherapy for muscle invasive bladder cancer: The ANZUP 1502 PCR-MIB trial.. Journal of Clinical Oncology. 36(6_suppl). TPS531–TPS531. 3 indexed citations

Gulley, James L., Michael Borre, Nicholas J. Vogelzang, et al.. (2018). Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer.. Journal of Clinical Oncology. 36(15_suppl). 5006–5006. 10 indexed citations

Iddawela, Mahesh, Carmel Pezaro, Pavel Sluka, et al.. (2018). Association of androgen receptor (AR) copy number gain with ARV7 expression and response to chemotherapy.. Journal of Clinical Oncology. 36(6_suppl). 180–180. 1 indexed citations

Goldstein, David, Rachel O’Connell, John Zalcberg, et al.. (2016). TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. Cancer Chemotherapy and Pharmacology. 78(2). 361–367. 14 indexed citations

10.

Parente, Phillip, et al.. (2015). Clinical perspectives: Practical insights from clinical experience with cabazitaxel in Australia. Asia-Pacific Journal of Clinical Oncology. 11(3). 199–207. 2 indexed citations

11.

Smith, Mitchell R., Robert E. Coleman, Laurence Klotz, et al.. (2014). Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Annals of Oncology. 26(2). 368–374. 117 indexed citations

12.

Ringash, Jolie, Heather‐Jane Au, Lillian L. Siu, et al.. (2013). Quality of life in patients with K‐RAS wild‐type colorectal cancer. Cancer. 120(2). 181–189. 12 indexed citations

13.

Ryan, Charles J., Mark Rosenthal, Siobhan Ng, et al.. (2012). Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone. Clinical Cancer Research. 19(1). 215–224. 64 indexed citations

14.

Bavbek, Sevil, Zafar Malik, Giuseppe Di Lorenzo, et al.. (2012). A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.. Journal of Clinical Oncology. 30(15_suppl). e15112–e15112. 3 indexed citations

15.

Eisenberger, Mario A., Anne‐Claire Hardy‐Bessard, Loı̈c Mourey, et al.. (2012). Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.. Journal of Clinical Oncology. 30(15_suppl). TPS4692–TPS4692. 5 indexed citations

16.

Ryan, Charles J., Matthew R. Smith, Johann S. de Bono, et al.. (2012). Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 30(15_suppl). LBA4518–LBA4518. 48 indexed citations

17.

Basser, R., Andrew Grigg, Jonathan Cebon, et al.. (2003). A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours. Annals of Oncology. 14(5). 788–794. 5 indexed citations

18.

Yoon, Kam Hon & Siobhan Ng. (2001). Early Onset Methotrexate-Induced Pancytopenia and Response to G-CSF: A Report of Two Cases. JCR Journal of Clinical Rheumatology. 7(1). 17–20. 11 indexed citations

19.

Ng, Siobhan, Mark Rosenthal, David M. Ashley, & Lawrence Cher. (2000). High-dose methotrexate for primary CNS lymphoma in the elderly. Neuro-Oncology. 2(1). 40–44. 59 indexed citations

20.

Ng, Siobhan, Mark Rosenthal, David M. Ashley, & Lawrence Cher. (2000). High-dose methotrexate for primary CNS lymphoma in the elderly. Neuro-Oncology. 2(1). 40–44. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact